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MICRO- AND NANOPARTICULATE 
CANCER VACCINES: A VISION 
FOR THE FUTURE
Micro/nanoparticles show promise for immunotherapy against 
cancer.
By Lipika Chablani, Ph.D., St. John Fisher College
F
ormulation scientists are con-
stantly challenged with unique 
opportunities to deliver che-
motherapeutic drug molecules 
to cancer patients. With the 
growing rate of cancer diagno-
ses, new therapies are being 
introduced to pave their way to 
the market. Along with drug delivery, these 
formulation approaches are being screened 
for formulation, design, and development of 
cancer vaccines. Can a vaccine be formu-
lated to obtain a protective or therapeutic 
immune response against cancer? 
Research proves that micro/nanoparticles 
loaded with unique cancer antigens and dec-
orated with immunostimulatory molecules 
are capable of activating the immune system 
against cancer. Priming the immune system 
provides a specific cytotoxic effect against 
the cancer cells. Thus, these microparticu-
late cancer vaccines activate the immune 
system and also limit the adverse effects on 
the healthy cells as seen with chemothera-
peutic agents. Several research studies in 
this direction are progressing to promising 
preclinical outcomes. 
CANCER VACCINES AND 
IMMUNOTHERAPY
The term cancer refers to about 200 diseases 
that share two common characteristics: an 
uncontrolled growth of cells and the ability 
to invade and damage normal tissues either 
locally or at distant sites in the body. Current 
advances in diagnostic methods allow health 
professionals to diagnose several cancer 
patients early and provide medical interven-
tions. With the advent of chemotherapy in 
the 1940s, there was an increasing need 
for drug delivery systems/formulations for 
these relatively toxic drug molecules. Several 
of these chemotherapeutic drug molecules 
are given intravenously and are associated 
with systemic adverse effects. Most of 
these chemotherapeutic drugs are limited 
by virtue of their dose-related toxicity, leaving 
the patient to move on to an alternative che-
motherapeutic regimen. Apart from chemo-
therapy, surgical removal of tumor masses 
and elimination of solid tumors via radiation 
is also commonly employed. However, all 
these methods are significantly invasive and 
debilitate the patient, impacting the quality 
of life. Additionally, many patients undergo 
a relapse and must revisit these challenges 
all over again. 
Considering the drawbacks of chemother-
apy, surgery, and radiation therapy, patients 
and health practitioners often seek noninva-
sive alternative therapies. A promising alter-
native is immunotherapy. Immunotherapy 
involves training patients’ own immune sys-
tems to fight against cancer and eliminate 
it. These immunotherapeutic approaches 
include application of various kinds of cancer 
vaccines to prime the immune system 
against cancer. Many ongoing preclinical 
and clinical studies aim to achieve a suc-
cessful cancer vaccine. 
Formulating a cancer vaccine is much 
more challenging than formulating an infec-
tious disease vaccine. A cancer vaccine is 
against a self-cell that has mutated and 
become cancerous. Thus, it is important to 
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prime the immune system judiciously to 
ensure an attack against cancer cells only 
and not healthy cells, which may resemble 
these cancerous cells in several aspects. 
Additionally, each cancer patient may be 
unique with a variable set of mutations 
requiring an individualized therapy to gain 
maximum efficacy. All these factors make 
formulation, design, and development of a 
cancer vaccine challenging and provide an 
opportunity for researchers to explore vari-
ous vaccine delivery systems. These vaccine 
delivery systems can enable us to prime 
the immune cells with unique tumor-asso-
ciated antigens (TAAs) that are expressed 
only by the tumor cells and thus generate 
an immune response against the cancer. To 
further boost the immune response gener-
ated by the vaccine, an adjuvant (an immuno-
stimulant) is included in the formulation. 
Upon generation of the immune response, 
if the vaccine is capable of inducing the 
memory cells of the immune system to 
remember the cancer antigens, the benefits 
will be multifold. Such memory immune 
responses are beneficial when the cancer 
relapses. Unlike conventional therapies, 
immunotherapy can potentiate the immune 
response against a relapsed tumor (if it 
expresses the same antigens) and eliminate 
it before it forms a mass. Thus, these cancer 
vaccines can provide long-term protection 
versus temporary relief. 
MICRO- AND NANOPARTICLES AS 
CANCER VACCINES
In the last decade, several preclinical stud-
ies have explored micro/nanoparticles for 
immunotherapeutic applications. These 
micro/nanoparticles have been formulated 
with different polymers, lipids, proteins, and 
adjuvants. Examples of such polymers, lipids, 
and proteins include cyclodextrins, cellu-
loses, phospholipids, poly (lactic-co-glycolic) 
acid (PLGA), and albumin.1-4 Formulation sci-
entists have employed techniques like spray 
drying and coacervation to prepare these par-
ticulate delivery systems, resulting in an opti-
mized and reproducible formulation. These 
micro- and nanoparticles may either encap-
sulate the vaccine antigens (tumor-specific 
antigens) or exist as a matrix of the polymer 
embedded with the vaccine antigens. The 
formulation design permits the inclusion of 
adjuvants to boost the immune response. 
Adjuvants like interleukins, GM-CSF, alum, 
and CpG have been evaluated with such 
vaccines. 
Irrespective of composition, these micro/
nanoparticles are within the average size 
range of 100 nm to 5 μm. This unique size 
range allows these micro/nanoparticles to 
mimic the infectious disease agents like 
bacteria/viruses, thus allowing the dendritic 
and macrophage cells, in vivo, to phagocy-
tose them preferentially. Upon phagocytosis, 
the particles are digested by the cellular 
enzymes, and the antigens are expressed by 
the dendritic cells via the major histocompat-
ibility complexes (major histocompatibility 
complex [MHC] I or II). These dendritic cells 
are capable of releasing immunostimula-
tory cytokines to activate both innate and 
adaptive immune systems. The adaptive 
immune system responds specifically to 
the antigens expressed by the dendritic cells 
and prepares an assault against any cancer 
cells expressing these antigens (Figure 1). 
Multiple boosters of these microparticulate 
vaccines induce a series of immunostimu-
latory responses and assist in eliminating 
the tumor burden. The results from preclini-
cal studies in this field depict that these 
micro/nanoparticulate vaccines are capa-
ble of generating tumor-specific adaptive 
immune responses and lead to the shrink-
age of tumor mass extending the life span 
of diseased animals.5-8  These results are 
promising and merit further investigation to 
prepare a cancer vaccine. 
Such particulate delivery systems include 
a range of nanocarriers including liposomes, 
virus-like particles, virosomes, polymeric par-
ticles, and nanoemulsions.9 Here are some 
of the notable advancements in the field 
of immunotherapy using these individual 
nanocarriers:
Liposomes 
Liposomal delivery systems consist of a 
phospholipid bilayer structure with an aque-
ous core, thereby accommodating both 
hydrophilic and lipophilic bioactive molecules, 
either by encapsulating them or embedding 
them in the bilayers respectively. DepoVax is 
an example of such a liposome-in-oil emul-
sion composed of cancer antigens and an 
adjuvant. The DepoVax platform includes 
liposomes containing cancer antigens and 
Montanide ISA51 VG as the adjuvant in the 
oil phase. This system has been evaluated 
under phase 1 clinical trials and has been 
shown to be safe and capable of inducing 
immune response against ovarian cancer. 
Additional clinical studies using this plat-
form are ongoing to evaluate the safety 
and immune response of the vaccine with 
low dose cyclophosphamide against ovarian 
cancer. Similarly, Tecemotide (Stimuvax or 
BLP25) was another liposomal cancer vac-
cine that paved its way through the phase 3 
clinical trials. The vaccine included the MUC1 
antigen, which is overexpressed by several 
cancers such as lung, breast, prostate, and 
colorectal. Along with the antigen, the vac-
cine consisted of monophosphoryl lipid A as 
the adjuvant. The preclinical and early clinical 
studies provided promising results; how-
ever, the recent phase 3 results evaluating 
the application of the vaccine against non-
small-cell lung cancer were unable to meet 
the primary outcomes of the study. Further 
evaluation of the vaccine candidate is under 
discussion and may need a new direction. 
Other significant advancements with 
liposomal vaccine delivery include use of 
pegylated liposomes to enhance the circula-
tion time of these delivery systems for an 
improved immune response. Cationic lipo-
somes and temperature- and pH-sensitive 
liposomes have been explored to augment 
the immune response generated by such 
liposomal cancer vaccines. Thus, combina-
tion of liposomal vaccine delivery systems 
along with the adjuvants and surface modi-
fications are some of the key developments 
in this area of research. 
Virus-like Particles and Virosomes 
Both virus-like particles (VLPs) and virosomes 
provide a unique particulate structure simi-
lar to viruses, thus making them inherently 
immunogenic as a vaccine carrier. The viral 
genome is missing in these structures, 
rendering them noninfectious and safe for 
prophylactic applications. 
VLPs have been successfully used to 
administer human papilloma virus (HPV) vac-
cine. These vaccines contain VLPs made of 
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Figure 1: Graphical representation of a microparticulate cancer vaccine. Upon administration of the vaccine mic-
roparticles, the dendritic cells are stimulated releasing inﬂ ammatory and/or anti-inﬂ ammatory cytokines. These 
activated dendritic cells are then capable of activating humoral (B cells) and cellular (T cells) adaptive immune 
responses to inhibit tumor growth.
only the major HPV coat or capsid protein 
L1. Cervarix and Gardisil are two of such 
VLP-based cancer vaccines that have been 
developed and commercialized. Cervarix 
is a bivalent and Gardisil is a quadrivalent 
vaccine containing either two (HPV 16/18) 
or four (HPV 16/18/6/11) L1 recombinant 
proteins. Findings from the clinical trials and 
use of these vaccines in the past few years 
have established their safety and efficacy in 
protection against cervical cancer caused 
by HPV. Both these vaccines are used pro-
phylactically and function by generation 
of neutralizing antibodies against the viral 
strains. Thus, the application of such VLP-
based cancer vaccines is limited to cancers 
caused by viruses and vaccines intended for 
prophylactic applications. 
Similarly, virosomes have gained signifi-
cance as a vaccine carrier for infectious dis-
eases such as influenza (Inflexal) and hepati-
tis A (Epaxal). Virosomes are unilamellar lipid 
viral vesicles comprised of phospholipids and 
glycoproteins acting as antigens for induction 
of immune response. These characteristic 
features allow them to mimic the infectious 
disease agents and generate a strong cel-
lular immune response. Immunopotentiating 
reconstituted influenza virosomes (IRIVs) are 
the most commonly used virosomes against 
infectious diseases. The IRIVs have been 
evaluated in preclinical studies as a cancer 
vaccine delivery system against melanoma 
and breast cancer as well. Further, using 
a similar approach, another class of viro-
somes—the Sendai virosomes—has been 
developed using the Sendai viruses. The 
viral envelope of Sendai viruses, used for 
these virosomes, hosts two types of glyco-
proteins, hemagglutinin-neuraminidase and 
the fusion protein. These two glycoproteins 
assist the virosomes to bind to the host-
cell surface and eventually fuse into their 
cell membranes. These properties make 
Sendai virosomes a suitable nanocarrier for 
delivery of bioactive molecules for cancer 
immunotherapy. 
Polymeric Particles 
Micro- and nanoparticulate delivery systems 
have been formulated using both natural and 
synthetic polymers. Such polymeric particles 
have been used as drug delivery systems as 
they are capable of targeting and reaching 
biological sites, which are otherwise inacces-
sible. Such particulate systems have been 
successfully used to deliver chemotherapeu-
tic drugs. Abraxane (human albumin-bound 
paclitaxel nanoparticle) is a good example of 
such a Food and Drug Administration (FDA) 
approved commercial nanoparticulate deliv-
ery system used for the treatment of breast, 
non-small-cell lung, ovarian, and pancreatic 
cancer. Researchers have attempted to trans-
late these albumin-incorporating nanoparticu-
late delivery systems to prepare a particulate 
cancer vaccine.4,7,10
A variety of polymeric particles have 
been formulated and evaluated for antigen 
delivery and potential use as a cancer vac-
cine. Some of the most commonly studied 
polymers for this purpose include PLGA, 
polylactide (PLA), albumin, gelatin, chito-
san, and cyclodextrin. The polymers are 
preferentially biodegradable, nontoxic, and 
nonimmunogenic to serve as a carrier. Fur-
ther, these polymeric particles provide the 
following advantages:
1) Protection of the cancer antigens (often 
susceptible to systemic degradation)
2) Enhanced uptake and presentation of 
the antigens via the MHC pathway
3) Sustained release of the antigens to 
obtain a prolonged effect of the vaccine
PLGA is one of the extensively stud-
ied polymers for immunotherapy and is 
also approved by FDA for drug delivery in 
humans. Research findings suggest that 
PLGA particles are well recognized by the 
dendritic cells and lead to effective antigen 
presentation and upregulation of inflamma-
tory cytokines responsible for induction of 
cellular immune response. These particles 
also possess adjuvant-like properties, boost-
ing the immune response further. However, 
the formulation of PLGA particles involves 
use of organic solvents and higher tempera-
tures, which may not be suitable for all the 
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